Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
Thomas Chatzikonstantinou(G. Papanikolaou General Hospital), Thomas Longval(Centre Hospitalier de Versailles), Gimena dos Santos(Northwestern University), Christos Demosthenous(G. Papanikolaou General Hospital), Deepesh Lad(Post Graduate Institute of Medical Education and Research), Kamel Laribi(Centre Hospitalier du Mans), Ιoannis Kotsianidis(Democritus University of Thrace), Yair Herishanu(Tel Aviv University), Bonnie Kho(Pamela Youde Nethersole Eastern Hospital), Rosa Collado(Hospital General Universitario De Valencia), Εliana Konstantinou(National and Kapodistrian University of Athens), Е. А. Дмитриева(Botkin Hospital), Jorge Labrador(Hospital Universitario de Burgos), Romain Guièze(Broad Institute), Marcos Daniel de Deus Santos(Universidade Federal do Espírito Santo), Lydia Scarfò(IRCCS Ospedale San Raffaele), Shaimaa El‐Ashwah(Mansoura University), Maria Dimou(National and Kapodistrian University of Athens), Maya Koren‐Michowitz(Jacksonville University), Gloria Iacoboni(Vall d'Hebron Hospital Universitari), José‐Ángel Hernández‐Rivas(Hospital Universitario Infanta Leonor), Miguel Alcoceba(Instituto de Investigación Biomédica de Salamanca), Alicia Enrico(Hospital Italiano La Plata), Eleftheria Hatzimichael(Thomas Jefferson University), Zadie Davis(Royal Bournemouth Hospital), Sean Harrop(The University of Melbourne), Dimitra Chamou(Centre for Research and Technology Hellas), Volkan Karakuş(Antalya Eğitim ve Araştırma Hastanesi), Maria Kislova(Botkin Hospital), Arnon P. Kater(Amsterdam University Medical Centers), Jana Kotašková(Central European Institute of Technology), Eva Gimeno(Hospital Del Mar), Valerio Guarente(University of Perugia), Andrzej Frygier(Hull York Medical School), Luca Laurenti(Fondazione Roma), Sofia Chatzileontiadou(AHEPA University Hospital), Elisabetta Albi(University of Perugia), Eva Minga(Centre for Research and Technology Hellas), Ozren Jakšić(University of Zagreb), Francesca Bacchiarri(University of Siena), Maria Efstathopoulou(Mansoura University), Zuzana Kubová(University Hospital Olomouc), Elżbieta Kalicińska(The University of Melbourne), Andrea Galitzia(Ospedale di Prato Santo Stefano), Salem Al‐Shemari(Kuwait University), David Donaldson(Endometriosis UK), Sara Galimberti(University of Pisa), Georgios Karakatsoulis(University of Ioannina), Thérèse Aurran‐Schleinitz(Institut Paoli-Calmettes), Barbara Dreta(University Hospital Centre Zagreb)
Cited by 2
Related Papers
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
|The Lancet|2007|679
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633
Global Burden of Multiple Myeloma
|JAMA Oncology|2018|631